Studies have demonstrated that low expression of ERCC1 within the tumors improves the response to chemotherapy based on cisplatin and the outcome of cancer by decreasing the removal of cisplatin- induced DNA adducts resulting in increased survival (21, 33-35). This evidence concerns the gene ERCC1 and cancer.